Topics:

Multiple sclerosis

Novel Rx for Multiple Sclerosis: IGF-1?

. IGF-1 could be used to treat MS
. IGF-1 stimulates T regulatory cells, suppressing T effector cells that reduce myelin
. IGF-1 is already approved for other uses, and might be quickly approved as a medication
 

FsdffsdFor people with MS, smoking is associated with more severe disease and faster disability progression. Smoking cessation before or after disease onset is associated with slower progression of disability.For people with MS, smoking is associated with more severe disease and faster disability progression. Smoking cessation before or after disease onset is associated with slower progression of disability.For people with MS, smoking is associated with more severe disease and faster disability progression. Smoking cessation before or after disease onset is associated with slower progression of disability. - See more at: http://www.neurologytimes.com/multiple-sclerosis#sthash.Aq5cH0PQ.dpuf

MS and Cigarettes: Where There’s Smoke, There’s Disease Progression

For people with MS, smoking is associated with more severe disease and faster disability progression. Smoking cessation before or after disease onset is associated with slower progression of disability.

- See more at: http://www.neurologytimes.com/multiple-sclerosis#sthash.P3SjVoYj.dpuf

For people with MS, smoking is associated with more severe disease and faster disability progression. Smoking cessation before or after disease onset is associated with slower progression of disability.

- See more at: http://www.neurologytimes.com/multiple-sclerosis#sthash.P3SjVoYj.dpuf
For people with MS, smoking is associated with more severe disease and faster disability progression. Smoking cessation before or after disease onset is associated with slower progression of disability. - See more at: http://www.neurologytimes.com/multiple-sclerosis#sthash.Aq5cH0PQ.dpuf

Multiple sclerosis

Approved for patients with relapsing forms of MS, the drug generally should be reserved for those who have had an inadequate response to 2 or more drugs indicated for MS treatment.

As more treatments become available, patients will have more preferences and will play a more prominent role in directing choices.

Determining who is at risk for MS remains difficult, and symptoms may take time to develop even in patients who already have some destroyed myelin. MRI may help.

A new study provides hope for MS treatment with IGF-1, which could ultimately halt the attack of T effector cells on myelin, thereby stopping disease progression.

New study findings do not suggest a need for a change in vaccine policy, but even a small increased risk could have an effect on public health.

Studies suggest that acupuncture can improve MS-related symptoms, but poor design makes it difficult to draw robust conclusions.

This, the least common MS disease course, carries the worst prognosis. Treatments are urgently needed to prevent or delay the rapid disease progression.

Pages

Subscribe to Multiple sclerosis on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.